Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 Apr;78(4):411-3.
doi: 10.1136/jnnp.2006.096008. Epub 2006 Oct 20.

How is disease progress in Friedreich's ataxia best measured? A study of four rating scales

M C Fahey  1 , L Corben, V Collins, A J Churchyard, M B Delatycki
Affiliations
Clinical Trial

How is disease progress in Friedreich's ataxia best measured? A study of four rating scales

M C Fahey et al. J Neurol Neurosurg Psychiatry. 2007 Apr.

Abstract

Background: Friedreich's ataxia (FRDA), the most common genetic cause of ataxia, is characterised by progressive neurodegeneration and cardiomyopathy. Initial treatments are likely to slow progression rather than reverse morbidity. An appropriate and sensitive scale to measure disease progress is critical to detect the benefit of treatments.

Objective: To compare the Friedreich Ataxia Rating Scale (FARS) with other scales proposed as outcome measures for FRDA.

Methods: 76 participants were assessed with the FARS and the International Cooperative Ataxia Rating Scale (ICARS) and 72 of these participants were also assessed with the Functional Independence Measure and the Modified Barthel Index. 43 participants had repeat measures at an interval of 12 months. Sensitivity and responsiveness were assessed using the effect size for each measure and the sample size required for a placebo-controlled clinical trial.

Results: The FARS showed a high correlation with the other three measures. A significant change in the score over 12 months was detected by the FARS, the International Cooperative Ataxia Rating Scale and the Functional Independence Measure. The FARS had the greatest effect size and requires fewer patients for an equivalently powered study.

Conclusions: Of the scales assessed, the FARS is the best to use in clinical trials of FRDA. This is based on effect size, and power calculations that show that fewer participants are required to demonstrate the same effect of an intervention. Further work is required to develop more sensitive and responsive instruments.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

References

    1. Durr A, Cossee M, Agid Y.et al Clinical and genetic abnormalities in patients with Friedreich's ataxia. New Engl J Med 19963351169–1175. - PubMed
    1. Voncken M, Ioannou P, Delatycki M B. Friedreich ataxia—update on pathogenesis and possible therapies. Neurogenetics 200451–8. - PubMed
    1. Hobart J C, Lamping D L, Freeman J A.et al Evidence‐based measurement: which disability scale for neurologic rehabilitation? Neurology 200157639–644. - PubMed
    1. Subramony S H, May W, Lynch D.et al Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 2005641261–1262. - PubMed
    1. Trouillas P, Takayanagi T, Hallett M.et al International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997145205–211. - PubMed

Publication types